HR deficiency was defined as either a deleterious tumour BRCA1/2 (tBRCA) mutation or a predefined HRD score ≥ 42 [8], which was determined in 57.8% (48/83) of TNBC patients (Fig. 2A, Table 1). This evidence concerns the gene BRCA1 and neoplasm.